TO B OR NOT TO B: B CELL DEVELOPMENT AND ANTIBODY RESPONSES TO EHV-1 IN HORSES
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
In my PhD research, I utilized pre-existing antibodies developed in my laboratory along with a novel IgD antibody, to characterize horse B cell populations in various developmental and immunological states in the peripheral blood. IgD, IgM, and CD23 were used to identify B cell populations earlier in development, while IgG1, IgG4, and CD23 were used to identify mature populations. In the first portion of this dissertation, I delved into the significance of B cell characterization. The sequential research chapters articulated how the incorporation of IgD can be used to better define the B cell profile in the peripheral blood of healthy horses and horses infected with EHV-1, at different stages of development. Lastly, I highlighted two primary antibody isotypes responsible for neutralizing EHV-1 and preventing viral infection, IgG1 and IgG4/7.